PT2977 Uses, Dosage, Side Effects and more
PT2977 is an HIF-2α inhibitor. A kidney cancer treatment, it is the lead candidate drug for Peloton. Peloton was acquired by Merck & Co Inc on May 21, 2019.
| Attribute | Details |
|---|---|
| Trade Name | PT2977 |
| Generic | PT2977 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Innovators Monograph
Search Medicines
